Articles On Antisense Therapeutics (ASX:ANP)

ShareCafeThe Week that Was – March 15-19, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so,...

ShareCafeIndustry Expert Sees the Path Forward for Antisense Therapeutics   Australian biotechnology company Antisense Therapeutics Limited (ASX: ANP) recently appointed Gil Price M.D., an experienced clinical physician trained in internal...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((LFG)) - Liberty Financial ((A2M)) - a2 Milk Co ((AMX)) - Aerometrex ((APT)) - Afterpay ((AGI)) - Ainsworth Game  ((AIZ)) - Air New Zealand ((ANP)) - Antisense Therapeuti...

Source: ShutterstockProfessional Summary Biotech penny stocks are extremely volatile, given the unpredictable nature of the biotechnology industry. Positive clinical developments and regulatory approvals for biotech penny players coul...

Antisense Therapeutics (ASX:ANP) says the US FDA has granted a 'Type C' guidance meeting that has been scheduled for 19 April 2021.

ShareCafeHidden Gems Webinar Recap – ANP, EMH, TNR, AOU – 5/2/21 Catch up on the full webinar with presentations from Antisense Therapeutics (ASX:ANP), European Metals (ASX:EMH), Torian Resources (ASX:TNR) & Auroch Minerals (ASX:AOU) H...

ShareCafeAntisense Therapeutics Limited (ASX: ANP) – Hidden Gems Webinar Presentation   Presenter – Mark Diamond, Managing Director & CEO – Antisense Therapeutics is a biotechnology company, developing and commercializing antisense pha...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

ShareCafeAntisense Therapeutics – Price Target Raised from $0.305 to $0.43 Corporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a placebo-controlled phase II trial involving ...

ShareCafeANP – Morgans rates the stock as Initiation of coverage with Add Stockbroker Morgans has initiated coverage of Antisense Therapeutics with a Speculative Buy rating and a maiden price target of 37.7c. In the stockbroker’s words, thi...

The Antisense Therapeutics Ltd (ASX: ANP) share price is storming high today. This comes as the biotech company made a recent announcement on a decision by the European Commission on one of its medicinal products. At the time of writing, t...

Summary Antisense Therapeutics has received Orphan Drug Designation for ATL1102 by the European Commission. The Company expects the incentives from ODD to be of very substantial commercial value. Earlier in October 2020, the Company r...

Antisense Therapeutics (ASX:ANP) says it has received notification that the European Commission has designated ATL1102 as an orphan medicinal product for Duchenne muscular dystrophy.

Antisense Therapeutics (ASX:ANP) says it has received notification that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion on its submission for Orphan Drug designation on ATL1102 fo...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

ShareCafeCorporate Connect Analyst Marc Sinatra Discusses Antisense Therapeutics (ASX:ANP) Corporate Connect Research analyst Marc Sinatra recently published a research report on Antisense Therapeutics (ASX:ANP) with a 30.5 cent valuation....

The US regulator has granted Antisense Therapeutics' (ASX:ANP) ATL1102 orphan designation for the treatment of Duchenne muscular dystrophy.

Summary Antisense Therapeutics announced today that it had received an Orphan Drug Designation grant from the US FDA for ATL1102 for the treatment of DMD. The Orphan Drug Designation offers protection of IP for ATL1102 in DMD with 7-yea...

Antisense Therapeutics chief executive Mark Diamond says the Melbourne biotech has hit a “very significant commercial milestone” after US regulators ... Read More The post Antisense Therapeutics receives FDA orphan designation for muscular...

By Peter Switzer, Switzer Report Lots of smaller companies I like One thing I’ve personally learnt this year is the power of small cap companies to drive your portfolio’s value higher. This revelation makes me even more committed to the ide...

ShareCafeAntisense Eyes A ‘Golden Ticket’ In The US – And Early European Approval For Its Rare Childhood Disease Therapy Two announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its n...

Investors have welcomed positive news for Australian company Antisense Therapeutics with the FDA moving its treatment for duchenne muscular dystrophy one step closer to possible approval.

Shareholders in Antisense Therapeutics, Amplia Therapeutics and Immutep all had reason to smile this week A trio of capital raisings ... Read More The post ScoPo’s Health Powerplays: The money keeps flowing for the ASX biotechs appeared fir...

Antisense Therapeutics (ANP) has submitted its antisense drug for Orphan Drug Designation with the US Food and Drug Administration (FDA), and is seeking similar designation in the European market with its application to the European Medicin...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Earnings s...

Melbourne-based small cap Antisense Therapeutics (ANP) aims to develop antisense drugs for under-researched diseases where there is a clear need for better treatments.

Money Talks is Stockhead’s regular drill down into the sectors and companies that investors have their eye on right now. Today, we hear from Lincoln Liu, associate director, Investment Banking of Rawson Lewis. Australia’s biotech sector is...

Antisense Therapeutics' [ASX:ANP) has announced it has submitted to the US FDA its application for orphan drug designation of ATL1102 for the treatment of Duchenne muscular dystrophy.

A quick wrap of the ASX’s key winners and losers on Thursday, July 30. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 783 stocks rose, 532 declined and 7...

ShareCafeWhat Have Been The Best “Hidden Gems” Webinar Performers? Over the past three months, ShareCafe has provided investors with the opportunity to connect and engage directly with many listed ASX companies. Our webinar series has provi...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The life s...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Victoria h...

ShareCafeAntisense Therapeutics – ShareCafe Hidden Gems Webinar Presentation   Antisense Therapeutics CEO Mark Diamond presents at the ShareCafe Hidden Gems Webinar on June 26, 2020. Antisense is an Australian publicly-listed biotechnology...

ShareCafeHidden Gems Webinar Recap – SPT, KZA, MEM, ANP   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the most recent edition with presentations from Splitit Payments Ltd (ASX:SPT), Kaz...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

Antisense Therapeutics (ASX:ANP) has announced the phase 2 trial of its immunomodulatory therapy (ATL1102) for Duchenne Muscular Dystrophy has met its primary endpoint and will now advance to a phase 2b study.

A quick wrap of the key winners and losers on Friday, May 22. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Code Company Price % Change Volume...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Now invest...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Antisense Therapeutics (ASX:ANP) is set to open up 25 per cent today after final clinical trial results suggest its drug could be a blockbuster for a nasty disease affecting little boys. The biotech’s immunomodulatory therapy, ATL1102 for D...

Biopharmaceutical company Antisense Therapeutics (ASX: ANP) emerged from a trading halt to announce that its immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) had met the required safety standards and achieved “strong...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve keen keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   This week’s big themes The ca...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Antisense Therapeutics (ASX:ANP) has announced that following the recent completion of the monitoring phase of the ATL1102 Phase 2 Duchenne Muscular Dystrophy (DMD) trial, the locking of the clinical trial database for final analysi...

The recent completion of the monitoring phase of Antisense Therapeutics Limited's (ASX:ANP) ATL1102 Phase II Duchenne Muscular Dystrophy (DMD) trial remains on track for the end of March 2020. As the trial is essentially completed, with all...

Antisense Therapeutics (ASX:ANP) has announced the appointment of Dr Gil Price as US-based consultant medical director.

Antisense Therapeutics Limited (ASX:ANP) announced on Thursday that it had appointed Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinical physician trained in internal medicine with a long-standing focus in drug developmen...